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 Late acute prosthetic joint infection (PJI) treated with surgical debridement and 8 
implant retention have a high failure rate, especially when caused by S. aureus. 9 
 The exchange of mobile components during surgical debridement is the most potent 10 
predictor for treatment success. 11 
 Preoperative risk factors for failure are: fracture as indication for the prosthesis, 12 
rheumatoid arthritis, an age above 80 years, male gender, chronic obstructive 13 
pulmonary disease, and a C-reactive protein >150 mg/L at baseline. 14 
 Treatment strategies for late acute PJIs should be individualized according to the 15 




Objectives: Debridement, antibiotics and implant retention (DAIR) is the recommended 20 
treatment for all acute prosthetic joint infections (PJI), but its efficacy in patients with late 21 
acute (LA) PJI is not well described. Methods: Patients diagnosed with LA PJI between 2005 22 
and 2015 were retrospectively evaluated. LA PJI was defined as the development of acute 23 
symptoms (≤ 3 weeks) occurring ≥ 3 months after arthroplasty. Failure was defined as: i) the 24 
need for implant removal, ii) infection related death, iii) the need for suppressive antibiotic 25 
therapy and/or iv) relapse or reinfection during follow-up. Results: 340 patients from 27 26 
centers were included. The overall failure rate was 45.0% (153/340). Failure was dominated 27 
by Staphylococcus aureus PJI (54.7%, 76/139). Significant independent preoperative risk 28 













prosthesis (odds ratio (OR) 5.4), rheumatoid arthritis (OR 5.1), age above 80 years (OR 2.6), 30 
male gender (OR 2.0) and C-reactive protein >150 mg/L (OR 2.0). Exchanging the mobile 31 
components during DAIR was the strongest predictor for treatment success (OR 0.35).  32 
Conclusion: LA PJIs have a high failure rate. Treatment strategies should be individualized 33 


















Prosthetic joint infections (PJI) can be subdivided into early post-surgical, chronic and late 40 
acute infections, the latter being considered to be mostly hematogenous of origin [1]. These 41 
subdivisions have been introduced to identify patients in whom the infected prosthesis can be 42 
debrided and retained (in case of acute infections) and to identify those in whom the infected 43 
prosthesis should be removed (in case of chronic infections). Despite these well-recognized 44 
categories of PJIs in literature, specific data on the clinical outcome of patients with a late 45 
acute infection is scarce. Several studies indicate that late acute PJIs have a higher failure rate 46 
compared to early acute (post-surgical) infections, especially when the infection is caused by 47 
Staphylococcus aureus (S. aureus) [2-8]. Some studies show higher failure rates in late acute 48 
PJIs caused by other microorganisms than S. aureus as well [9-10], but this has been 49 
discarded by others [11-13]. Current guidelines recommend the same surgical (debridement 50 
and implant retention (DAIR)) and antimicrobial strategy for both early and late acute 51 
infections [14], but late acute PJIs may require a different treatment approach. More evidence 52 
on the clinical outcome and identification of risk factors for failure in a larger cohort of 53 
patients is important to optimize treatment for this specific patient group. Therefore, we 54 
performed a large multicentre observational study to describe clinical outcome and risk 55 
factors for failure in late acute PJI treated with DAIR. We hypothesized that late acute PJIs 56 
have a high failure rate, especially when caused by S. aureus. 57 
 58 
 59 
MATERIAL AND METHODS 60 
 61 













We performed an international multicenter retrospective observational study in which data of 63 
all consecutive patients with a late acute PJI between January 2005 and December 2015 were 64 
collected. All patients who underwent surgical debridement according to the surgical records 65 
were retrospectively evaluated. If centers were not able to provide cases during the complete 66 
study period, a minimum of at least 10 consecutive cases was required to participate in the 67 
study. In each center, all DAIR procedures performed within the studied period according to 68 
the surgical records were evaluated, and only cases that met the strict definition of late acute 69 
PJI were included. Late acute PJI was defined as patients, with a prior history of normal 70 
function of the index arthroplasty, who developed a sudden onset of symptoms and signs of a 71 
PJI, such as acute pain and/or swelling of the prosthetic joint, more than 3 months after the 72 
implantation. Patients with a sinus tract and/or symptoms existing for longer than 3 weeks 73 
before surgical debridement were excluded from the analysis. Informed consent was retrieved 74 
when required by the ethics committee of the participating center. A PJI was defined 75 
according to the diagnostic criteria described by the Musculoskeletal Infection Society 76 
(MSIS) [15]. Multiple variables on patient characteristics, clinical presentation, medical 77 
microbiology results, surgical & antibiotic treatment and outcome were collected and 78 
analyzed.  79 
 80 
Clinical outcome  81 
Failure was defined as: i) the need for prosthesis removal due to persistent or recurrent 82 
clinical signs of infection  (one or two-stage exchange, amputation, Girdlestone for hips or 83 
arthrodesis for knees) due to persistent clinical signs of infection, ii) the need for suppressive 84 
antibiotic therapy because of persistent clinical or biochemical signs of infection, iii) a relapse 85 
of infection with the same microorganism during follow-up, iv) a reinfection with a different 86 













PJI related death was defined as death that occurred during (antibiotic) treatment with no 88 
other alternative explanation than an uncontrolled infection. The need for a second 89 
debridement during antibiotic therapy was not considered as failure. Patients in whom 90 
antibiotic suppressive therapy was prescribed for other reasons than persistent signs of 91 
infection (e.g. because this was routine practice of the participating hospital and/or because 92 
the patient had severe comorbidity and was therefore, not eligible for future surgeries) were 93 
excluded. Failure was subsequently categorized into early failure: persisting or reappearance 94 
of symptoms of infection during antibiotic treatment, and late failure: reappearance of 95 
symptoms of infection after finishing antibiotic treatment. Complete remission was 96 
considered in patients with a retained and functional implant after 2 years of follow-up. A 97 
functional implant was defined as the ability to walk without pain.  98 
 99 
Statistical analysis 100 
A Chi-square test (or a Fisher exact-test when appropriate) was used to analyze the difference 101 
between groups for categorical variables, and a student t-test (or Mann Witney U test when 102 
data was not normally distributed) for continuous variables. A Kaplan Meier survival curve 103 
with a cox-regression analysis was used to evaluate failure rate in time. Possible risk factors 104 
for failure were selected and analyzed using univariate analysis by Pearson’s correlation. 105 
Variables with a significance level of < 0.2 were analyzed in a binary multivariate logistic 106 
regression model. A separate CART (classification and regression tree) analysis was 107 
performed to assess which variable was the most potent in predicting treatment outcome. All 108 
variables were tested for multicollinearity and additionally analyzed in a cox regression 109 
analysis. Preoperative variables with the highest odds ratio (OR) in the multivariate logistic 110 
regression model were included in a risk score, in which the beta coefficient of each variable 111 













late failure. In the analysis of early failure, late failures were considered as non-failures and 113 
included as such. All analyses were two-tailed and p-values < 0.05 were considered as 114 
statistically significant. Data were presented as mean ± Standard Deviation (SD) when data 115 
was normally distributed or median ± Inter Quartile Range (IQR) when data was not normally 116 
distributed. Statistical analysis was performed using SPSS, version 23.0 (SPSS Inc., Chicago, 117 





Characteristics of late acute PJI 123 
A total of 340 cases were included in the analysis. From the total cohort, 247 out of 340 cases 124 
(72.6%) had a PJI of the knee. Isolated microorganism(s) on patient level are shown in Table 125 
1. Surprisingly, coagulase negative staphylococci (CoNS) were isolated in 30 cases (8.8%), 126 
including 24 monomicrobial infections. After exclusion of S. lugdunensis (n=4), a pathogen 127 
with a higher virulence compared to other CoNS, 1 out of 20 CoNS PJIs had bacteremia 128 
(bloodcultures taken in 10 out of 20 cases), and none of them was diagnosed with 129 
endocarditis.  In 170 out of 340 cases (50%) a source of the PJI was identified: i) skin 130 
infection (n=62, 36.5%), ii) dental procedure (n=18, 10.6%), iii) recent surgery (n=24, 131 
14.1%), or iv) other (n=66, 38.8%). A preceding skin infection was described in 35/139 132 
(25.2%) of S. aureus and in 22/97 (22.7%) of streptococcal infections. In gram-negative PJIs, 133 
recent surgery or another source than skin infection, was marked in 21 out of 50 cases (42%).  134 
 135 













The overall failure rate of late acute PJI was 45.0% (153/340). With a limited number of 137 
cases, failure rate was highest in PJI caused by Enterococcus species (72.7%, 8/11). There 138 
was no major difference in failure rate between Enterococcus species: treatment failed in 4 139 
out of 5 cases (80%) with E. faecium and in 4 out of 6 cases (67%) with E. faecalis. The 140 
overall treatment failure was dominated by S. aureus, with a failure rate of 54.7% (76/139). 141 
The average failure with other microorganisms was around 40% (CoNS 40.0% (12/30), 142 
Streptococcus species 37.1% (36/97), gram-negatives 36.0% (18/50)). Patients with an 143 
unidentified source of infection showed a trend towards a higher failure rate (58.8%, 90/184) 144 
compared to those with an identified source of infection (41.2%, 63/156) (p 0.12). The 145 
percentage of failure in time according to the Kaplan-Meier survival curve is depicted in 146 
Figure 1. 147 
Early failure occurred in 53.5% of failed cases (82/153), which mostly resulted in the need for 148 
implant removal (73.0%, 60/82) and in death due to the infection (13.4%, 11/82). The median 149 
time to failure during antibiotic therapy was 26 days (IQR 12 – 89). Late failure occurred in 150 
46.5% of cases (71/153) and was mostly due to a relapse of infection with the same 151 
microorganism during follow-up (63.3%, 45/71), followed by reinfection with another 152 
microorganism (11.2%, 8/71). The remaining patients were put on suppressive antibiotic 153 
therapy because of persistent signs of inflammation and/or had a relapse of infection without 154 
an identified microorganism. The median time to failure after finishing antibiotic therapy was 155 
6 months (IQR 4 – 11), in which 81.1% of patients failed within the first year after DAIR. 156 
The median follow-up of non-failures was 25.0 months (IQR 11 –  31). Seventy-two of the 157 
non-failures had a follow-up of 2 years, in whom complete remission was achieved in 75% 158 
(54/72).  159 
 160 













The median days of intravenous (IV) antibiotic treatment was higher in failures compared to 162 
non-failures (22 days (IQR 12 – 42) versus 19 days (IQR 10 – 34) respectively, p 0.007). To 163 
analyze the effect of the total duration of IV and oral antibiotic treatment, early failures were 164 
excluded from the analysis. The rate of late failure was the same for those treated for less than 165 
60 days (28.5%, 51/179) compared to those treated for more than 60 days (25.3%, 20/79) (p 166 
0.56).  167 
To exclude empirical antibiotic treatment, the type of antibiotic was only analyzed if 168 
prescribed for more than five days (Supplementary Table 2). For staphylococcal infections in 169 
whom data on the oral regimen was available, the failure rate was 49.3% (66/134) when 170 
rifampin was added versus 67.7% (21/31) when rifampin was not added to the antibiotic 171 
regimen (p 0.06). In addition, failure rate was significantly lower when rifampin was 172 
combined with a fluoroquinolone compared to other regimens (failure rate 45.5% (46/101) 173 
versus 64.1% (41/64), respectively, p 0.02). In the rifampin treated cases, there was no 174 
significant difference in failure rate in fluoroquinolone-based regimens compared to other 175 
antibiotics (46.0% (46/100) vs 58.8% (20/34), respectively, p 0.20). For streptococci, failure 176 
rate was 22.7% (5/22) when rifampin was added versus 42.5% (31/73) when rifampin was not 177 
added to the antibiotic regimen (p 0.13). With a limited number of gram-negative PJIs 178 
analyzed, the use of fluoroquinolones was not associated with treatment success in our 179 
analysis (failure rate of 34.3% (12/35) when using a fluoroquinolone versus 38.5 % (5/13) 180 
when using another antibiotic regimen, p 0.79). 181 
 182 
Risk factors for failure  183 
Table 2 shows the results of the univariate and multivariate binary logistic regression analysis 184 
in identifying risk factors for failure. From the total of 340 cases, all variables were complete 185 













blood cultures were obtained were considered as blood culture negative. The results of the 187 
multivariate analysis for other variables did not change when the blood culture variable was 188 
omitted from the analysis. The Hosmer and Lemeshow test had a p-value of 0.89, indicating 189 
that the model was adequate, with a predicting capacity of 71.1% according to the 190 
classification table.  191 
Male gender, age above 80 years, rheumatoid arthritis (RA), fracture as indication for the 192 
prosthesis, C-reactive protein (CRP) above 150 mg/L, infection caused by S. aureus and the 193 
use of local antibiotics were all significant independent variables for failure in the 194 
multivariate analysis. Local antibiotic therapy mainly consisted of gentamicin beads or 195 
gentamicin sponges. There were no significant clinical differences between patients who were 196 
treated with local antibiotics compared to patients in whom it was withheld (data not shown), 197 
with the exception of the American Society of Anesthesiologist (ASA) classification score, 198 
which was higher in the local antibiotic group (ASA score ≥ 3 in 66.7% (20/30) versus 44.3% 199 
(102/230) respectively, p 0.02). With an OR of 2.9, COPD was also associated with a higher 200 
failure rate, although it did not reached statistical significance. Cox regression analysis 201 
showed the same predictors for failure. Analysis on multicollinearity revealed that COPD was 202 
accompanied by a higher prevalence of ischemic heart disease and heart failure. Exchanging 203 
the mobile components during DAIR was the only variable that was independently associated 204 
with treatment success. In addition, according to the CART analysis, exchanging the mobile 205 
components was the most potent variable in predicting treatment outcome.  206 
Multivariate analysis showed that COPD, RA, CRP above 150 mg/L and Enterococcus 207 
species were significant independent predictors for early failure, while S. aureus was the only 208 
predictor for late failure (Supplementary Table 1).   209 
Based on the results of the multivariate binary logistic regression, a risk score was developed, 210 













possibility to exchange the mobile components can be known preoperatively as well, the 212 
protective effect of exchanging the mobile components during DAIR was also included 213 
(Figure 2A). Because failure was dominated by S. aureus, a separate analysis was performed 214 
for the presence or absence of S. aureus (Figure 2B-C). Our results indicate that the 215 
preoperative model has the strongest predictive value for failure in PJIs caused by other 216 
microorganisms than S. aureus. In S. aureus PJI in whom mobile components were 217 
exchanged during DAIR, the rate of failure decreased from 47.1% to 36.6% when patients 218 
were treated with a fluoroquinolone in combination with rifampin. 219 
 220 
Blood culture positive versus blood culture negative cases 221 
Since cases with positive blood cultures are considered as the ‘classical’ late acute / 222 
hematogenous infections, we performed an additional analysis on blood culture positive 223 
versus proven blood culture negative cases. Table 3 shows the clinical differences between 224 
both groups. From the 259 cases in whom blood cultures were obtained, 42% (109/259) were 225 
blood culture positive. The rate of bacteremia was higher in hip PJIs and in implants of more 226 
than 2 years of age, and was more often associated with fever, infections caused by S. aureus 227 
and endocarditis. Echocardiography was performed in 72.5% of cases with S. aureus 228 
bacteremia (50/69). In the majority, this mainly comprised transthoracic echocardiography 229 
(53.6%). Endocarditis was diagnosed in 10% of cases (7/69). The overall failure rate was 15% 230 
higher in blood culture positive cases and was mostly ascribed to early failure (p 0.01) 231 
(Supplementary Table 1). From the failures in the blood culture positive group, 9 out of 61 232 
cases (14.8%) died because of the infection. All of these 9 cases, with the exception of one, 233 
















Due to the low incidence of late acute PJIs [16], clinical data and specific treatment 238 
recommendations for this subgroup of patients is limited. By the effort of many centers 239 
involved, we were able to describe the clinical characteristics of late acute PJIs, evaluate its 240 
outcome, and identify risk factors for failure. In a large cohort of 340 late acute PJIs treated 241 
with DAIR, we demonstrated a failure rate of 45%, in which treatment failure was most 242 
prominent when caused by S. aureus.  243 
The high failure rate observed in our study may partly be explained by: i) The presence of an 244 
unidentified source of infection in case of bacteremia. Although not statistically significant, 245 
an unidentified source of infection was associated with a higher failure rate in our study. 246 
Endocarditis may have been underdiagnosed in our study, as a transesophageal 247 
echocardiography was not performed in all S. aureus bacteremias. Thus, continuous seeding 248 
of bacteria to the prosthetic joint with the development of biofilm may be the cause of failure 249 
in these cases. Indeed, we demonstrated that a relapse of infection during follow-up was 250 
mostly caused by S. aureus, which supports this hypothesis. However, it is important to note 251 
that the reported incidence of endocarditis in S. aureus bacteremia in literature is comparable 252 
to our study [17], and failure rate was still 40% in blood culture negative cases. ii) A 253 
previously unrecognized chronic PJI. Although we held on to a clear definition of a sudden 254 
onset of symptoms in a priorly asymptomatic joint, we cannot completely rule out that 255 
chronic PJIs that deteriorated acutely also comprised a small part of the cohort. CoNS were 256 
identified in a limited number of patients and these microorganisms are not common 257 
pathogens for causing acute infections. Indeed, most of these cases were blood culture 258 
negative and were not diagnosed with endocarditis, which makes an acute infection in these 259 
cases unlikely. However, the failure rate in CoNS was not higher than in others (40%), and 260 













culture negative cases  iii) Mobile components were not exchanged in almost half of our 262 
studied cohort. As the CART analysis showed that this is the most potent variable for 263 
predicting failure, treatment success may be substantially higher when mobile exchange was 264 
performed in all cases. The low number of exchange may be due to the fact that the study 265 
extends over ten year time period and only in recent years, the importance of this surgical 266 
technique became clear. In addition, mobile components are not available in acute settings in 267 
some centers. However, even with the exchange of mobile components, overall failure rate 268 
was still 36%, and even higher in case of S. aureus infections. 269 
At the moment, a DAIR procedure is the recommended surgical approach for all acute PJIs 270 
with stable implants and susceptibility to potent anti-biofilm regimens [14]. Our data suggest 271 
that a DAIR should be reconsidered in late acute PJIs for certain patient categories. As 272 
previously mentioned, especially S. aureus PJI has a high risk of failure, especially when 273 
mobile components cannot be exchanged and treatment with a rifampin-based regimen is not 274 
possible. Failure rate was much lower in a study performed by Tande et. al., in which late 275 
acute PJI caused by S. aureus was treated with revision surgery or if the DAIR was followed 276 
by chronic suppressive antibiotic therapy [8]. Therefore, identifying the causative 277 
microorganism and its susceptibility pattern preoperatively may be helpful to choose the best 278 
surgical approach in an acute setting. To elaborate, studies have shown that Gram staining of 279 
synovial fluid has a poor sensitivity in diagnosing PJI, but its value is mostly evaluated in 280 
chronic cases, and may be more useful and sensitive in acute infections [18]. Unfortunately, 281 
early molecular detection does not show any benefit so far in acute PJIs, but its diagnostic 282 
accuracy maybe optimized in upcoming years  [19]. For late acute PJIs caused by another 283 
microorganism than S. aureus, the CRIME80 score could be useful in identifying high-risk 284 
patients. According to our analysis, patients who received a prosthetic implant because of a 285 













shown, that these variables are also strongly correlated with failure in early postsurgical and 287 
chronic PJIs [5, 11, 20].  In addition, our data indicate that patients with male gender, COPD, 288 
a CRP above 150 mg/L at presentation and an age above 80 years are also more prone to fail. 289 
Accordingly, a DAIR procedure is probably not advisable in late acute PJI with a high a priori 290 
chance of failure. In addition, some studies suggest that revision surgery applied as salvage 291 
therapy after DAIR failure is associated with poorer outcome [21-22]. Therefore, our results 292 
suggest the need for revision surgery as a first surgical approach .  293 
Non-surgical strategies to increase the chance of treatment success seem limited. In our study, 294 
the addition of rifampin in staphylococcal infections, especially when combined with a 295 
fluoroquinolone, improved treatment outcome, which is in accordance with previous findings. 296 
[2,23]. A longer duration of intravenous antibiotic treatment and/or the use of local antibiotics 297 
was associated with a higher failure rate, but this may be due to selection bias as antibiotic 298 
treatment is most often intensified in more severe infections. Indeed, we found a higher ASA 299 
classification score in patients who received local antibiotics compared to patients in whom 300 
local antibiotics was withheld. Therefore, the exact value of local antibiotics, the type of 301 
antibiotic, the use of chronic suppressive therapy and certain antibiotic combinations should 302 
be addressed in future studies, ideally in a randomized controlled study design. For this 303 
reason, we want to emphasize that our results on the effect of antibiotic treatment on clinical 304 
outcome should be evaluated in light of the aforementioned limitations and interpreted with 305 
caution.  306 
In conclusion, late acute PJIs treated with DAIR have a high failure rate, especially when 307 
caused by S. aureus and without the exchange of mobile components. Treatment strategies 308 
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Figure 1. Kaplan-Meier survival curve late acute PJI treated with DAIR.  388 
Survival is defined as treatment success, as described in the material and method section. A. Overall survival 389 
(n=340). B. Survival categorized in PJI caused by S. aureus  (n=139, including 10 cases with polymicrobial 390 
infection), Enterococcus spp (n=11 including 4 cases with polymicrobial infection) and other microorganisms 391 
(n=190).  C. Survival according to the exchange of mobile components during debridement. In the survival 392 


















Figure 2. Failure rate according to CRIME80 risk score. 399 
The risk score was developed according to the results of the multivariate bivariate regression analysis, including 400 
preoperative variables that were independently associated with failure, and exchange of mobile components as a 401 
predictor for treatment success as depicted in Table 1. A. Overall failure (n=340). B. Failure rate in S.aureus 402 
negatives cases (n=201). C. Failure rate in S. aureus positive cases (n=139). COPD: Chronic Obstructive 403 
Pulmonary Disease, CRP: C-Reactive Protein. 404 
 405 
Table 1. Isolated microorganisms.  406 
*Other: Salmonella spp (3),  Morganella morganii (3),  Serratia marcescens (2), Acinetobacter baumannii (1), 407 
H. influenza (1), Helicobacter cinaedi (1), Campylobacter fetus (1). 408 
Isolated microorganism(s) n (%) 
Gram positives 
Staphylococcus aureus 
   Methicillin susceptible S. aureus 
   Methicillin resistant S. aureus  
Staphyloccocus lugdunensis  
Other coagulase negative staphylococci 
Enterococcus species 
Streptococcus species 
   Streptococcus pyogenes 
   Streptococcus dysgalactiae 
   Streptococcus agalactiae 


























Table 2. Risk factors for failure.  410 
*Variables included in the multivariate binary logistic 411 
regression analysis. 
1
Patients in whom no bloodcultures 412 
were obtained were considered as bloodculture negative 413 
cases. BMI: Body Mass Index, ASA: American Society of Anesthesiologist, COPD: Chronic Obstructive 414 
Pulmonary Disease, CRP: C-Reactive Protein, DAIR: Debridement, Antibiotics and Implant Retention. 415 
 416 
Table 3. Characteristics blood culture positive and bloodculture negative cases (n=259). Cases in whom 417 
bloodcultures were not obtained were excluded from the analysis (n=81).  418 
   Streptococcus anginosus  
   Group viridans streptococci, not specified 
   Group G streptococci, not specified 






















   Including S. aureus 
   Including Enterococcus species 
   Including Streptococcus species 
   Including coagulase negative staphylococci 
   Including Gram negatives 












 Non-failures Failures Unadjusted OR 
(95% CI) 





Age > 80 years 
BMI > 30 












1.41 (0.92 – 2.17) 
1.65 (0.98 – 2.78) 
0.81 (0.47 – 1.37) 







2.02 (1.05 – 3.89) 
 





































0.99 (0.64 – 1.53) 
1.48 (0.77 – 2.86) 
1.12 (0.56 – 2.45) 
1.19 (0.73 – 1.92) 
1.63 (0.79 – 3.32) 
0.75 (0.33 – 1.69) 
1.49 (0.44 – 4.97) 
0.65 (0.06 – 7.22) 
















2.9 (0.99 – 8.68) 
 
 
1.76 (0.59 – 5.35) 





















1.34 (0.77 – 2.33) 




































0.78 (0.48 – 1.26) 
3.32 (1.14 – 9.69) 
1.65 (1.03 – 2.66) 
0.93 (0.32 – 2.75) 
0.93 (0.52 – 1.67) 












5.39 (1.42 – 20.46) 
1.21 (0.60 – 2.45) 
 
 










Duration of symptoms > 10 days 
Temperature > 38.5°C 
Physical signs of inflammation 
CRP > 150 mg/L 




















1.66 (0.98 – 2.80) 
1.53 (0.90 – 2.61) 
0.68 (0.38 -1.19) 
1.29 (0.82 – 2.02) 
0.93 (0.49 – 1.74) 
1.91 (1.20 – 3.02) 










1.21 (0.54 – 2.74) 
1.84 (0.84 – 4.03) 
1.81 (0.74 – 4.45) 
2.00 (1.04 – 3.86) 
 























1.85 (1.19 – 2.86) 
1.73 (0.68 – 4.42) 






3.52 (1.78 – 6.96) 
 





Surgical techniques DAIR 
Exchange of mobile components 
> 1 DAIR 










0.52 (0.33 – 0.81) 
1.93 (0.96 – 3.86) 






0.35 (0.18 – 0.67) 
2.30 (0.88 – 6.02) 


















Supplementary Table 1. 420 
Risk factors for early and 421 
late failure. 422 
Results of multivariate 423 
binary logistic regression 424 
analysis for early failure 425 
(n=81) and late failure 426 
(n=72) in a total of 340 427 
cases. *p-values <0.2 were included in the multivariate regression analysis. 428 
 429 
Supplementary Table 2. Oral antibiotic regimen.  430 
 Blood culture positive 
(n=109) 
Blood culture negative 
(n=150) 
p-value  





















Duration of symptoms > 10 days 
Temperature > 38.5°C 
Physical signs of inflammation 
















































 Non-failures Early Failures p-value  Adjusted OR   
(95% CI) 





Age > 80 years 
BMI > 30 






























































































4.26 (1.62 – 11.17) 
1.14 (0.35 – 3.76) 
0.98 (0.11 – 8.64) 
2.58 (0.79 – 8.37) 















































0.09 (0.01 – 0.82) 
 
 




















































































































1.58 (0.79 – 3.15) 
 
 










Duration of symptoms > 10 days 
Temperature > 38.5°C 
Physical signs of inflammation 
CRP > 150 mg/L 































2.14 (1.01 – 4.54) 
 


































1.56 (0.72 – 3.35) 


















































Surgical techniques DAIR 
Exchange of mobile components 
> 1 DAIR 














0.43 (0.21 – 0.88) 



















0.75 (0.39 – 1.43) 



















 n (%) 
S. aureus (n=136) 





























Streptococcus species (n=95) 
Amoxicillin 
Clindamycin 
Linezolid 
Rifampin-based regimen 
 
55 (57.9%) 
12 (12.6%) 
4 (4.2%) 
22 (23.1%) 
